Search | Clinical Trials Finder

Conditions: COVID-19
Interventions: Degarelix, Saline; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 11 more

Conditions: Healthy
Interventions: GLYX-13, IV normal saline; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Pasadena, California

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoporotic Fractures, Osteoporosis, Postmenopausal
Interventions: Zoledronic acid, vitamin D, calcium, Saline; Drug · Dietary Supplement · Other
Lead sponsor: Susan L. Greenspan; Other
Eligibility: 65 Years and older · Female only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New Kensington, Pennsylvania

Conditions: Dry Eye
Interventions: Ocular Surface Immune Globulin (OSIG), Placebo; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Subcutaneous Fat
Interventions: CBL-514 Injection, Placebo; Drug · Other
Lead sponsor: Caliway Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Chicago, Illinois • Omaha, Nebraska • Nashville, Tennessee + 1 more

Conditions: Vitreoretinal Traction Syndrome
Interventions: Plasmin, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes
Interventions: Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test; Drug · Dietary Supplement · Other
Lead sponsor: University of Florida; Other
Eligibility: 12 Years to 45 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Secondary Progressive Multiple Sclerosis (SPMS)
Interventions: NG01 - Autologous bone marrow derived human stromal cells, Sodium Chloride 0.9%; Biological · Other
Lead sponsor: NeuroGenesis Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Group B Streptococcal Infections
Interventions: IVT GBS-06, Placebo; Biological
Lead sponsor: Inventprise Inc.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Sleep Apnea, Chronic Nasal Congestion
Interventions: Oxymetazoline Hydrochloride, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Extreme Immaturity
Interventions: Sodium chloride, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 7 Days to 8 Days
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Clostridium Difficile Infection
Interventions: Clostridium difficile vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 17,535 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 220
States / cities: Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more

Conditions: Abnormalities, Cardiovascular
Interventions: Volanesorsen, Moxifloxacin, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Osteoarthritis, Knee
Interventions: Cingal, Triamcinolone Hexacetonide (TH), Placebo; Drug
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 21 more

Conditions: Healthy, HIV
Interventions: Tenofovir disoproxil fumarate intravaginal ring, Placebo intravaginal ring (IVR); Drug
Lead sponsor: Marla Keller; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Sphingomyelin Lipidosis
Interventions: placebo (saline), Olipudase alfa; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Decatur, Georgia • The Bronx, New York

Conditions: Glabellar Frown Lines
Interventions: Botulinum Toxin A, Placebo; Drug
Lead sponsor: Croma-Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Interventions: Givosiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 10
States / cities: Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more

Conditions: Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
Interventions: Hydrocortisone, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Congestive Heart Failure, Renal Insufficiency
Interventions: Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule; Drug
Lead sponsor: Barnes-Jewish Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Typhoid VI Polysaccharide Vaccine Injectable Solution, Saline Placebo (0.5mL injection); Biological · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity
Interventions: 4% Lidocaine, Saline; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

OSIG-eye Drops Treatment for Dry Eye Disease

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

Neulasta in Type 1 Diabetes

Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

Sodium Supplementation and Growth in Very Low Birth Weight Infants

Clostridium Difficile Vaccine Efficacy Trial

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Corticosteroids to Treat Pancreatitis

Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction

Inflammatory Challenge and Fear

Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery